I

Instituto Medico Rio Cuarto | Research Center | Rio Cuarto, Argentina

Research site

(Unclaimed)

Location

Hipolito Irigoyen 1020, Rio Cuarto, Cordoba, Argentina

Site insights

Top conditions

Top treatments

Pembrolizumab

TAR-200

Rilematovir

Sotatercept

Vixarelimab

MK-7962-005

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

3 of 10 total trials

A Long-term Follow-up Study of Sotatercept for PAH Treatment (MK-7962-004/A011-12) (SOTERIA)

This study is being conducted to assess the long-term safety, tolerability, and efficacy of sotatercept (MK-7962, formerly called ACE-011) in partici...

Active, not recruiting

PAH

Pulmonary Arterial Hypertension

Biological: Sotatercept

A Study of TAR-200 in Combination With Cetrelimab or TAR-200 Alone Versus Intravesical Bacillus Calmette-Guérin (BCG) in Participants With BCG-naïve High-risk Non-muscle Invasive Bladder Cancer (HR-NMIBC) (SunRISe-3)

The purpose of this study is to compare event-free survival (EFS) in participants with Bacillus Calmette-Guerin (BCG)-naive high-risk non-muscle inva...

Active, not recruiting

Bladder Cancer

Biological: Cetrelimab

Drug: TAR-200

Phase 3 Inhaled Novaferon Study in Hospitalized Patients With Moderate to Severe COVID-19 (NOVATION-1)

This study is a randomized, double-blind, multicenter, placebo-controlled trial to evaluate the safety and efficacy of a novel therapeutic agent, Nov...

Enrolling

Covid19

Biological: Placebo

Biological: Novaferon